secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001104659-25-120141
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3
-------------------------------------------------------------------------------

- 18 patients enrolled; 17 remain on therapy; safety consistent with known profile.
- 6 of 8 patients at Month 3 achieved BMI reduction; 3 of 5 at Month 6 saw BMI reduction.
- 6 of 7 evaluable patients at Month 3 had meaningful hyperphagia (HQ-CT) score reduction.
- Company plans to advance setmelanotide into Phase 3 registrational trial in PWS.
- Initiated Phase 1 Part D of weekly MC4R agonist RM-718 in up to 20 PWS patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925120141/0001104659-25-120141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925120141/rytm-20251211x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-120141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer